患有血管缩患者的决策:一项初步研究
Muriel Méchenin1, Jacques-Olivier Fortrat1
1Equipe CarMe, MITOVASC, SFR ICAT, CNRS, INSERM, Médecine Vasculaire, CHU Angers, Faculty of Medicine, Université d'Angers, 49933 Angers, France.
Biology
|July 29, 2023
概括
患有情绪/血恐惧症昏迷的个体表现出决策能力受损,在冲突任务中表现出较慢的反应时间,与对照人群相比. 这表明与恐惧症相关的昏迷有不同的临床途径和潜在的治疗点.
科学领域:
- 神经科学是一个神经科学.
- 心理学 心理学 心理学
- 心脏病学 心脏病学
背景情况:
- 情绪/血恐惧症昏迷和静止性昏迷是不同的情况.
- 了解决策任务中的绩效差异对于差异诊断至关重要.
研究的目的:
- 为了比较情绪/血恐惧症昏迷和静止昏迷的受试者之间的决策冲突任务表现.
- 为了研究高脑功能在血压控制中的作用,与昏迷类型相关.
主要方法:
- 基于计算机的西蒙任务被用来评估冲突管理能力.
- 被试被分为控制,情绪/血恐惧症昏迷和静止性昏迷组.
主要成果:
- 情绪/血恐惧症昏迷患者在决策冲突期间表现出显著延迟的反应时间 (55.8±17.7毫秒).
- 对照组 (20.5 ± 4.9毫秒) 和静态 (13.4 ± 9.2毫秒) 的反应时间更快.
结论:
- 情绪/血恐惧症昏迷和静态昏迷代表着单独的临床实体.
- 决策过程可能是情绪/血恐惧症的治疗目标.
- 与恐惧症相关的昏迷中改变决策强调了高级大脑功能在心血管调节中的参与.
相关概念视频
Dysrhythmias VII: Nursing Management of Dysrhythmias
15
Nursing management of dysrhythmias involves the following:AssessmentSubjective Assessment:The initial step involves gathering patient-reported symptoms such as dizziness, palpitations, and chest discomfort. It is crucial to collect a detailed history, including previous heart conditions, current medication use, and lifestyle factors like caffeine and alcohol consumption.Objective Assessment:This involves observing clinical signs such as jugular venous distention, cool and pale skin, and...
15
Assessment of the Cardiovascular System I: Subjective Data
368
A thorough health history and physical assessment are essential for identifying cardiovascular disease (CVD) symptoms and distinguishing them from other health issues.
Initial Enquiry
Ask the patient about their primary concern and thoroughly explore all reported symptoms.
Medical History
Investigate past illnesses affecting the cardiovascular system, such as angina, anemia, rheumatic fever, congenital heart disease, stroke, thrombophlebitis, dysrhythmias, varicosities
Inquire about symptoms...
Initial Enquiry
Ask the patient about their primary concern and thoroughly explore all reported symptoms.
Medical History
Investigate past illnesses affecting the cardiovascular system, such as angina, anemia, rheumatic fever, congenital heart disease, stroke, thrombophlebitis, dysrhythmias, varicosities
Inquire about symptoms...
368
Heart Failure Drugs: β-Blockers
364
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
364
Acute Coronary Syndrome III: Diagnostic Studies
10
Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
10
Heart Failure V: Medical Management
13
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
13
Dysrhythmias VI: Management of Dysrhythmias
19
Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
19


